← Directory

Omega Funds

PE / VC · Boston · United States

Address
888 Boylston Street, Suite 1111, Boston, MA 02199
Email
Website
LinkedIn
Founded
2004
AUM
$1 600 M
Ticket
$10-50 m

Stages

Series BSeries ASeedPre-seedLate Stage (Series C+)

Investment region

North AmericaEurope

Industries

MedTechAISoftwareRoboticsPharmaceuticalsMedical DevicesMedia and EntertainmentHealthcare ServicesGamingFoodtechFood and BeverageFintechFinancial ServicesConsumer Services (B2C)Consumer ProductsBiotechnologyLife SciencesHealthTech

Profile

Omega Funds is a venture capital firm based in Boston, Massachusetts, and Geneva, Switzerland, focusing on the future of medicine. They are known for their strategic investments in fields such as oncology, immunology, rare diseases, and precision medicine. Their team consists of experienced professionals dedicated to helping entrepreneurs and founders increase their odds of success by leveraging their extensive network and commitments to transformative medicinal solutions. They aim to invest in exceptional founders and impactful products, with a strong emphasis on fostering successful public listings and acquisitions. Omega Funds invests in a variety of sectors within the healthcare and life sciences industries, supporting early-stage to late-stage companies primarily in North America and Europe. They have participated in multiple funds, including Omega Fund IV through Omega Fund VIII, demonstrating significant capital commitments in these areas. They focus on strategic partnerships to bring impactful products and platforms to market. Notable investments by Omega Funds include companies that have achieved key milestones such as public listings and acquisitions, significantly impacting the healthcare industry. They have helped bring 54 products to market, showcasing their influence and effectiveness in the medical investment landscape.

Kontakte (2)

NameTitleEmailTelefonLinkedIn
Partner — — —
Partner at Omega Funds — — —

Name, email and phone are partially hidden. Subscribe to see them in full.